Compare TBPH & TRUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TBPH | TRUP |
|---|---|---|
| Founded | 2013 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 824.9M | 948.7M |
| IPO Year | 2013 | 2014 |
| Metric | TBPH | TRUP |
|---|---|---|
| Price | $16.66 | $23.81 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 5 |
| Target Price | $18.40 | ★ $45.80 |
| AVG Volume (30 Days) | 320.5K | ★ 342.9K |
| Earning Date | 05-04-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 279.13 | ★ 295.65 |
| EPS | N/A | ★ 0.11 |
| Revenue | $15,386,000.00 | ★ $1,439,305,000.00 |
| Revenue This Year | $8.46 | $11.79 |
| Revenue Next Year | N/A | $8.83 |
| P/E Ratio | ★ N/A | $215.00 |
| Revenue Growth | N/A | ★ 11.95 |
| 52 Week Low | $10.82 | $21.16 |
| 52 Week High | $21.03 | $57.35 |
| Indicator | TBPH | TRUP |
|---|---|---|
| Relative Strength Index (RSI) | 53.70 | 52.90 |
| Support Level | $16.07 | $21.16 |
| Resistance Level | $17.21 | $29.24 |
| Average True Range (ATR) | 0.33 | 0.91 |
| MACD | 0.06 | 0.32 |
| Stochastic Oscillator | 79.70 | 69.28 |
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
Trupanion Inc is a specialty insurance products provider in the United States. Its core business is the sale of insurance products tailor-made for pets, especially cats and dogs. It operates in two business segments: The subscription business segment generates revenue majorly from subscription fees related to the company's direct-to-consumer products and Other business segment is comprised of revenue from other product offerings that generally have a business-to-business relationship and a different margin profile than subscription business segment, including revenue from writing policies on behalf of third parties and revenue from other products and software solutions. Geographically, the company operates in United States, which derives maximum revenue; and Canada and Others.